Rezolute, Inc. (NASDAQ:RZLT) Receives Consensus Recommendation of “Hold” from Analysts

Shares of Rezolute, Inc. (NASDAQ:RZLT) have earned a consensus rating of “Hold” from the eleven brokerages that are presently covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and five have given a buy rating to the company. The average 1 year target price among brokerages that have issued a report on the stock in the last year is $7.6250.

Several equities research analysts have recently commented on RZLT shares. BTIG Research reissued a “buy” rating and set a $5.00 price target on shares of Rezolute in a research note on Thursday, January 8th. Guggenheim reduced their price objective on Rezolute from $15.00 to $6.00 and set a “buy” rating for the company in a report on Friday, December 12th. Cantor Fitzgerald downgraded Rezolute from an “overweight” rating to a “neutral” rating in a research report on Thursday, December 11th. Weiss Ratings reissued a “sell (d-)” rating on shares of Rezolute in a report on Thursday, January 22nd. Finally, Wedbush raised their price target on Rezolute to $2.00 and gave the company a “neutral” rating in a research report on Thursday, January 8th.

Institutional Investors Weigh In On Rezolute

A number of large investors have recently added to or reduced their stakes in the business. BNP Paribas Financial Markets acquired a new position in Rezolute during the second quarter worth about $25,000. ExodusPoint Capital Management LP acquired a new stake in shares of Rezolute in the fourth quarter valued at approximately $25,000. HB Wealth Management LLC acquired a new stake in shares of Rezolute in the fourth quarter valued at approximately $26,000. Fifth Third Wealth Advisors LLC purchased a new position in shares of Rezolute during the 4th quarter worth approximately $29,000. Finally, Hsbc Holdings PLC purchased a new position in shares of Rezolute during the 4th quarter worth approximately $29,000. 82.97% of the stock is owned by institutional investors and hedge funds.

Rezolute Trading Up 0.6%

RZLT stock opened at $2.49 on Friday. The company has a market cap of $237.81 million, a P/E ratio of -2.67 and a beta of 0.51. Rezolute has a 52 week low of $1.07 and a 52 week high of $11.46. The company’s 50-day moving average price is $3.12 and its 200 day moving average price is $5.94.

Rezolute (NASDAQ:RZLT) last issued its earnings results on Thursday, February 12th. The company reported ($0.22) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.06). On average, equities research analysts expect that Rezolute will post -0.93 earnings per share for the current year.

About Rezolute

Rezolute, Inc, a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, an oral plasma kallikrein inhibitor, which is in clinical trial for the chronic treatment of diabetic macular edema.